ImpediMed Past Earnings Performance

Past criteria checks 0/6

ImpediMed has been growing earnings at an average annual rate of 4.1%, while the Medical Equipment industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 20.9% per year.

Key information

4.1%

Earnings growth rate

46.3%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate20.9%
Return on equity-38.1%
Net Margin-186.2%
Next Earnings Update30 Apr 2024

Recent past performance updates

Recent updates

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Mar 05
ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Nov 23
Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

Jul 11
Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Mar 27
We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10
We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01
A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12
Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08
ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Nov 25
How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Revenue & Expenses Breakdown
Beta

How ImpediMed makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:IPD Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2310-19260
30 Sep 2311-20260
30 Jun 2311-21251
31 Mar 2311-21251
31 Dec 2211-22261
30 Sep 2211-21251
30 Jun 2211-20241
31 Mar 2210-20231
31 Dec 2110-19231
30 Sep 219-20241
30 Jun 218-21251
31 Mar 217-20232
31 Dec 206-19222
30 Sep 206-20223
30 Jun 206-21223
31 Dec 195-25243
30 Sep 195-24233
30 Jun 194-24233
31 Dec 184-25263
30 Sep 183-26283
30 Jun 183-27303
31 Mar 184-28303
31 Dec 174-28304
30 Sep 175-28305
30 Jun 176-28295
31 Mar 176-28306
31 Dec 166-29316
30 Sep 166-27305
30 Jun 166-26284
31 Mar 166-23253
31 Dec 155-20222
30 Sep 155-17202
30 Jun 155-15171
31 Mar 154-13151
31 Dec 144-10130
30 Sep 144-9120
30 Jun 144-8100
31 Mar 143-7100
31 Dec 133-790
30 Sep 133-8100
30 Jun 133-8101

Quality Earnings: IPD is currently unprofitable.

Growing Profit Margin: IPD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IPD is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare IPD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: IPD has a negative Return on Equity (-38.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.